CLPT
ClearPoint Neuro, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
9.47
P/S
7.54
EV/EBITDA
-12.99
DCF Value
$-17.22
FCF Yield
-8.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.4%
Operating Margin
-65.4%
Net Margin
-69.1%
ROE
-122.2%
ROA
-33.4%
ROIC
-27.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $10.4M | $-7.8M | $-0.27 |
| FY 2025 | $37.0M | $-25.5M | $-0.90 |
| Q3 2025 | $8.9M | $-5.9M | $-0.21 |
| Q2 2025 | $9.2M | $-5.8M | $-0.21 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.18
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.